Medical devices with local drug delivery capabilities

Information

  • Patent Grant
  • 8888684
  • Patent Number
    8,888,684
  • Date Filed
    Monday, March 27, 2006
    18 years ago
  • Date Issued
    Tuesday, November 18, 2014
    9 years ago
Abstract
A medical device, for example, an endoscope or catheter, includes local drug delivery capabilities for selectively delivering at least one drug in vivo. The local drug delivery may occur as the medical device is advanced through tortuous passageways of the patient's body or may occur after the medical device has reached its targeted destination. The medical device includes a drug agent, for example, carried in or on a hydrophilic or hydrogel coating disposed on the outside thereof. When the hydrogel or drug agent receives an appropriate signal, e.g., solution containing a triggering agent or triggering condition, e.g., heat or light, the hydrogel contracts or expands to squeeze out the drug from hydrogel. If electric current is provided as the signal, and the drug agent is charged, the drug agent is released by electrophoretic forces.
Description
FIELD OF THE INVENTION

The present invention is directed to devices suitable for use in medical procedures and, more particularly, to medical devices such as endoscopes, catheters, or the like, that include local drug delivery capabilities.


BACKGROUND OF THE INVENTION

An endoscope is a piece of surgical equipment that has imaging capabilities so as to be able to provide images of an internal body cavity of a patient. Most minimally invasive surgical procedures performed in the gastrointestinal (GI) tract or other internal body cavities are accomplished with the aid of an endoscope.


Endoscopes are essentially formed by a flexible shaft that is introduced into the GI tract after being inserted in the body cavity, starting from the anus or from the mouth of a subject. The endoscope typically includes a steerable tip to facilitate navigation of the endoscope through the GI tract, and is typically of sufficient stiffness so that it can be advanced along the body cavity without buckling. The tip of the endoscope that is introduced in the GI tract can be outfitted with several devices, most notably an illumination device and a vision device, such as a vision integrated circuit, so that the operator of the endoscope can examine the interior of the GI tract and maneuver the tip of the endoscope into the proper position.


Endoscopes are typically utilized in extremely tortuous passageways, such as the GI tract, which requires the endoscope to be advanced by pushing on the proximal end of the scope while steering the tip inside the passageway, the endoscope thereby exerting pressure against the walls of the passageway. Such advancing techniques, in conjunction with the configuration of the endoscope and the GI tract, can result in localized patient discomfort or pain as the endoscope is pressed against the lumen wall during manipulation. At times when the endoscope is advanced, “looping” occurs, a condition where the endoscope forms a coiled shape when inserted. The loop may cause the side of the endoscope to press against the lumen wall, for example, the intestine, and distend the intestinal wall instead of advancing along the intestine. In conventional endoscope systems, patient discomfort is reduced in patients undergoing endoscopic GI procedures through the use of sedation. However, there are risks associated with the use of sedatives. Therefore, a need exists to provide localized anesthesia to a patient undergoing an endoscopic procedure.


SUMMARY OF THE INVENTION

Embodiments of the present invention are directed to medical devices and, in particular, to endoscopes that reduce or eliminate the need for sedation in a patient by providing localized drug delivery. By administering drugs such as sedative drug agents locally at the region of pain or discomfort during an endoscopic procedure, the overall amount of drugs administered to the patient is lowered, thereby reducing the potential risks inherent in administering sedatives to a patient. Embodiments of the present invention may also be used to deliver other types of drug agents via an endoscope, such as therapeutic drug agents.





BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing aspects and many of the attendant advantages of this invention will become more readily appreciated by reference to the following detailed description, when taken in conjunction with the accompanying drawings, wherein:



FIG. 1 is a perspective view of one embodiment of a medical device, in particular, an endoscope constructed in accordance with aspects of the present invention;



FIG. 2A is a partial longitudinal cross-sectional view of the endoscope shown in FIG. 1;



FIG. 2B is a magnified partial longitudinal cross-sectional view of the endoscope shown in FIG. 2A;



FIG. 2C is a magnified partial longitudinal cross-sectional view of the endoscope shown in FIG. 2A having an outer layer comprising a porous structure including one or more drug agents, in accordance with an embodiment of the present invention;



FIG. 2D is a cross-sectional view of the endoscope shown in FIG. 2A having an outer layer comprising a plurality of microchannels including one or more drug agents, in accordance with an embodiment of the present invention;



FIG. 2E is a magnified partial longitudinal cross-sectional view of the endoscope shown in FIG. 2A having an outer layer comprising a porous layer comprising one or more drug agents covered with a hydrogel layer, in accordance with an embodiment of the present invention;



FIG. 3 is a partial perspective view of one embodiment of a distal tip section of the endoscope of FIG. 1;



FIG. 4 is a partial longitudinal cross-sectional view of another embodiment of a medical device, in particular, an endoscope constructed in accordance with aspects of the present invention;



FIG. 5 is a partial longitudinal cross-sectional view of another embodiment of an endoscope formed in accordance with aspects of the present invention;



FIG. 6 is a partial longitudinal cross-sectional view of another embodiment of an endoscope formed in accordance with aspects of the present invention;



FIG. 7 is a partial longitudinal cross-sectional view of another embodiment of an endoscope formed in accordance with aspects of the present invention;



FIG. 8A is a partial longitudinal cross-sectional view of another embodiment of an endoscope formed in accordance with aspects of the present invention; and



FIG. 8B is a magnified partial longitudinal cross-sectional view of another embodiment of an endoscope formed in accordance with aspects of the present invention;





DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS

Embodiments of the present invention will now be described with reference to the drawings, where like numerals correspond to like elements. Embodiments of the present invention are directed to devices of the type broadly applicable to numerous medical applications in which it is desirable to insert an imaging device, catheter, or similar device into a body lumen or passageway. Specifically, embodiments of the present invention are directed to medical devices having local, targeted drug delivery capabilities. Several embodiments of the present invention are directed to medical devices having local drug delivery capabilities that incorporate endoscopic features, such as illumination and visualization capabilities, for endoscopically viewing anatomical structures within the body. As such, embodiments of the present invention can be used for a variety of different diagnostic and interventional procedures including colonoscopy, upper endoscopy, bronchoscopy, thoracoscopy, laparoscopy, and video endoscopy, etc., and are particularly well suited for negotiating tortuous passageways of the patient's body. Although exemplary embodiments of the present invention will be described hereinafter as endoscopes, it will be appreciated that aspects of the present invention have wide application and may be incorporated into other medical devices such as catheters, where local, targeted drug delivery is desirable. Accordingly, the following descriptions and illustrations herein should be considered illustrative in nature and, thus, not limiting the scope of the present invention as claimed.



FIG. 1 illustrates one exemplary embodiment of a medical device and, in particular, an endoscope 20 constructed in accordance with aspects of the present invention. The endoscope 20 has a proximal end 26 and a distal end 28. The proximal end 26 may be functionally connected to a control console (not shown) that operates the endoscope 20. The endoscope 20 includes an elongated shaft-like body 36 comprised of a proximal shaft section 40, an optional articulation section 44, and a tip section 48 disposed at the distal end 28 of the endoscope 20.


In one embodiment, the endoscope 20 is at least partially covered with an outer layer 230 along its shaft-like body 36. The outer layer 230 may cover the entire endoscope 20 or any selected portion or portions thereof. In one embodiment, the outer layer 230 has a lubricious outer surface constructed of a hydrophilic material that allows the endoscope 20 to be advanced more easily through the passageways of the patient. In one embodiment, the outer layer 230 includes localized drug delivery capabilities for selectively delivering at least one drug in vivo, such as when the endoscope is advanced through the tortuous passageways of the patient's body, as described in more detail below.


Referring now to FIGS. 2A-2B, the proximal shaft section 40 comprises an elongated tubular construction having an axial, centralized lumen 60 and an outer surface 62. The centralized lumen 60 is sized to allow for endoscope components, such as optics, working devices, fluid channels, and the like, to be routed to the tip section 48 of the endoscope 20. Additionally, the centralized lumen 60 allows for the passage of electrical wires or fluid delivery tubes, as will be described in more detail below. The proximal shaft section 40 is flexible, i.e., bendable, but substantially non-compressible (e.g., non-kinkable) along its length. The proximal shaft section 40 may be of any suitable construction and made of any suitable material. In one embodiment, the proximal shaft section 40 may be made of a polymeric material such as a polyurethane, polyimide, PTFE, polyethylene, or a high strength thermoplastic elastomer, such as a polyether bock amide (Pebax®) or the like, and combinations thereof. If desired, the proximal shaft section 40 may be reinforced along its length to increase its torsional stiffness. For example, the shaft section 40 may include wire reinforcements as described in copending U.S. patent application Ser. No. 10/811,781, filed Mar. 29, 2004, and U.S. patent application Ser. No. 10/956,007, entitled “Video Endoscope,” filed Sep. 30, 2004, the disclosures of which are hereby incorporated by reference.


At the distal region of the endoscope 20 adjacent the distal end of the proximal section 40 is an optional articulation section 44, as best shown in FIG. 1. The articulation section 44, in use, allows the distal end 28 to be selectively steered, manipulated, or bent in one or more planes by action occurring at the proximal end of the endoscope 20. The articulation section 44 may allow the tip section 48 to be turned back on itself, i.e., over an arc of up to 180 degrees, and can be directed to bend in any direction desired about the circumference of the distal tip section. That is, the operator can select both the amount of the bend or articulation and the direction of the bend. For several non-limiting examples of articulation sections that may be practiced with the present invention, please see copending U.S. patent application Ser. No. 10/811,781, filed Mar. 29, 2004, U.S. Pat. No. 5,846,183, and U.S. patent application Ser. No. 10/956,007, entitled “Video Endoscope,” filed Sep. 30, 2004, the disclosures of which are hereby incorporated by reference.


Returning to FIG. 1, the body of the endoscope 20 includes a tip section 48 that is connected to the distal end of the articulation section 44. FIG. 3 illustrates one embodiment of a tip section 48 that comprises a cylindrical body having a distal section 120 and a proximal section 124. The tip section 48 is preferably made of a biocompatible plastic of which many examples have been described hereinabove. As will be described in detail below, the distal section 120 defines side surfaces 126 to which light sources may be mounted. The distal face 128 of the distal tip section 48 includes a number of ports including an imaging device port 136, one or more illumination ports 140, an access port 144 for a working channel lumen, and an insufflation/irrigation port 148.


As best shown in FIG. 3, an image sensor (not shown) that preferably comprises a charged coupled device (CCD), CMOS imaging sensor, or other solid state imaging device and one or more glass or polymeric lenses that produce electronic signals representative of an image of the scene in front of the imaging device port 136 is fitted within the imaging device port 136. The signals may be routed to a video processing and display device at the proximal end of the endoscope through transmission cabling 154 that is routed through the centralized lumen of the endoscope. The image sensor is preferably a low noise, CMOS color imager such as VGA, SVGA, SXGA, or XGA. If less resolution is desired, a ½ VGA sensor could also be used. For conventional video systems, a minimum frame rate of 25 to 30 fps is required to achieve real-time video. The video output of the system may be in any digital or analog format, including conventional formats such as PAL or NTSC, or high definition video format.


The illumination port 140 houses one or more lenses at the distal end of a fiber optic bundle 160. The fiber optic bundle 160 is routed through the centralized lumen from the proximal end 26 to the distal end 28 of the endoscope 20. The fiber optic bundle 160 transmits light generated at the proximal end of the endoscope by, for example, a laser or high intensity lamp source, to the distal end of the endoscope where it is emitted from the illumination port 140. Alternatively, the illumination ports 140 house one or more light emitting diodes (LEDs) that are not shown for ease of illustration. The LEDs may be high intensity white light sources or may comprise colored light sources such as infrared (IR), visible lights, e.g., red, green, blue, or ultra-violet (UV) LEDs. With colored LEDs, images in different spectral bands may be obtained due to illumination with any one or more individual colors. White light images may be obtained by the simultaneous or sequential illumination of the colored LEDs and combining individual color images at each illumination wavelength. If sequential illumination of colored LEDs is employed, as an alternative, a monochrome CMOS imager can be used.


The access port 144 is the termination point of a working channel 180 of the endoscope 20 that extends from outside the proximal end of the endoscope 20 to the distal end through the centralized lumen of the endoscope. The working channel 180 is defined by a sheath that is non-collapsible (e.g., non-kinkable) and thus tends to maintain a circular cross section even when it is bent along its axis. The working channel 180 can also include a reinforcement coil to help maintain its cross-sectional shape. The working channel 180 tends to retain a constant size when the sheath is used so that binding of the tools inserted in the working channel 180 is prevented and the cross-sectional shape is resistant to collapse during suction.


The flush port 148 is connected in fluid communication with an irrigation and insufflation lumen 188 for discharging liquid and air from the distal face 128 of the distal tip section 48. In one embodiment, the liquid and air are preferably discharged from the flush port 148 in the direction of the imaging device port 136 and/or the illumination ports 140. The irrigation/insufflation lumen 188 is routed from the proximal end 28 of the endoscope to the distal tip section 48 through the centralized lumen of the endoscope. The proximal end of the irrigation/insufflation lumen 188 is adapted for connection to a source of irrigation/insufflation fluids disposed externally from the endoscope. It will be appreciated that the irrigation/insufflation lumen 188 may alternatively be two separate lumens, thus necessitating two flush ports.


Referring now to FIG. 2A, steering of the distal end 28 of the endoscope 20 can be carried out in a convenient manner by using a plurality of control cables 204 that extend longitudinally through the endoscope 20 from the proximal end and terminate at or near the distal end of the endoscope 20.


As shown in FIG. 2B, the endoscope 20 may be at least partially covered with an outer layer 230 along its shaft-like body 36 for providing the endoscope 20 with a friction-reducing outer surface. The outer layer 230 preferably comprises a hydrophilic material that is biocompatible and capable of carrying drug agents by absorption, chemical bonding, e.g., ionic, covalent, and/or by other conventional techniques, as will be described below. In some embodiments of the present invention, the hydrophilic material is a lubricious coating constructed from a hydrophilic polymer that allows selective release of one or more drug agents disposed therein. Hydrophilic polymers suitable for use as hydrophilic lubricous coatings, such as polyacrylamide, are known in the art. In other embodiments, the layer 230 comprises a hydrogel coating that is composed largely of water molecules, such as polyuronic acid or other polymeric hydrogel coatings. The outer layer 230 may additionally contain other hydrophilic polymers and other lubricious ingredients in addition to the hydrophilic polymer hydrogel. The outer layer 230 may be attached to the outer surface 62 of the shaft-like body 36 using any art-recognized method. For example, the outer layer 230 may be attached through the reaction of organic functional groups on the hydrophilic polymers with a crosslinking agent contained in the catheter body. As another example, the outer surface of the shaft-like body may be treated to allow covalent attachment of the layer 230.


In accordance with one aspect of the present invention, the endoscope 20 further includes local drug delivery capabilities that allow selective administration of a drug agent in vivo. In some applications, selective release of drug agents such as analgesic or sedative agents is initiated via a user input signal to allow for drug agent release in a specific location where the patient is feeling some discomfort as the endoscope 20 is routed through the patient's body. In one embodiment, the endoscope 20 utilizes electrophoretic forces to selectively release the drug agent from the endoscope during use. As will be described in greater detail below, embodiments of the present invention may include other drug release signals or stimuli such as light, heat (i.e., thermal), chemical, acoustic, etc., for selectively releasing the drug agent from the endoscope in vivo.


Referring now to FIGS. 2A-2B, there is shown a longitudinal cross-sectional view of one embodiment of the endoscope 20 having local drug delivery capabilities that utilize electrophoresis to selectively administer the drug agent at chosen locations. As best shown in FIG. 2B, a drug agent 250 is carried by, impregnated, or otherwise disposed in or on the outer layer 230.



FIG. 2C is a longitudinal cross-sectional view of the shaft 36 shown in FIG. 2A, illustrating an embodiment of the outer layer 230 comprising a porous structure including a plurality of nanopores 252 having drug agents 250 disposed therein.



FIG. 2D is a cross-sectional view of the shaft 36 shown in FIG. 2A, illustrating an embodiment of the outer layer 230 comprising a plurality of microchannels 254 having drug agents 250 disposed therein. The microchannels 254 may be oriented in any direction.



FIG. 2E is a partial longitudinal cross-sectional view of the shaft 36 shown in FIG. 2A illustrating an embodiment of the layer 230 comprising a first porous region 256 having one or more drug agents 250 embedded therein, and a second hydrophilic region 258 at least partially covering the first porous region 256. The hydrophilic region 258 may comprise a hydrophilic material such as hydrogel. The drug agent 250 may also be disposed within the hydrophilic region 258.


In one embodiment, the one or more drug agents 250 is delivered locally to the patient through the outer layer 230. In such embodiments, the one or more drug agents 250 is preferably charged molecules that are delivered locally to the patient via electrophoresis. In one embodiment, the outer layer 230 is a hydrogel such as a polyacrylamide hydrogel and the drug agent 250 is an analgesic or sedative agent having an electric charge, which is capable of being released from the hydrogel outer layer through electrophoresis. Any suitable analgesic or sedative drug agents 250 having an electric charge may be used in accordance with an embodiment of the shaft 36. For example, procaine, lidocaine-HCL, benzocaine, cocaine, bupivacaine, ropivacaine, prilocalne, and mepicaine chloroprocaine, or polar derivatives thereof, may be used in accordance with various embodiments of the invention.


Other neutral charged analgesics or sedative agents, as well as other drug agents, for example, therapy drug agents (e.g., anti-inflammatory, antibiotics, etc.), may also be used if combined with a charged carrier. For example, a neutral or a weakly charged drug agent can also be used if it can be converted to a charged moiety. There are a variety of ways for carrying out such a conversion, as known in the art. For instance, one typical method includes forming an emulsion of the drug or drug particle with a surfactant. Examples of surfactants that can be used are, without limitation, fatty acids, phospholipids, and sodium acetyl sulfate. In another known method, the drug agent can be converted to a charged moiety by cyclodextrin encapsulation.


The drug agent 250 may be uniformly or non-uniformly dispersed in or on the outer layer 230. For example, the concentration of the drug agent may be constant along the length of the endoscope or may have greater or lesser concentrations along the length, including gaps where little or no drug agent is present. Additionally, the concentration of the drug agent around the circumference of the endoscope may have either constant or varying concentrations, including little or no drug agent being present. Further, the concentration of the drug agent may be constant or non-constant throughout the thickness of the outer layer 230. In some embodiments, the drug agent 250 may be attached as a surface layer to a portion of the endoscope surface having an electron charge. For example, the drug agent 250 may be attached as a surface deposit in any suitable configuration, such as in one or more channels or in a spiral pattern.


The endoscope 20 further includes a drug release control that signals the release of the drug agent 250 from the outer layer 230. The drug release control may be specifically selected based on the drug to be delivered and/or the outer layer to be used. In one embodiment, the endoscope 20 utilizes electromotive forces to selectively release the drug agent from the outer layer 230 by electrophoresis, as will now be described in more detail. In the embodiment shown in FIGS. 2A-2B, the drug release control of the endoscope 20 includes a plurality of electrodes 260 disposed in between the outer surface 62 of the shaft-like body 36 and the inner surface of the layer 230. Alternatively, the electrodes 260 may be suspended or imbedded in the outer layer 230. The electrodes 260 may be selectively arranged along the length of the endoscope and around the circumference of the endoscope proximate the disposed drug agent 250, as desired. In the embodiment of the present invention illustrated in FIGS. 2A-2B, the electrodes 260 are in the form of rings and arranged in an array. The spacing between the electrodes 260 along the shaft may be constant or may vary, depending on the application.


The electrodes 260 may be electrically isolated from one another via insulators 264. The insulators 264 may be formed from ceramic, glass, glass-ceramic, polytetrafluoroethylene (PTFE), polyimide, or a number of other materials that are non-conductive and biocompatible. In one embodiment, the electrodes 260 are preferably made of copper or gold and affixed to the shaft-like body via vapor deposition or other techniques known in the art. It will be appreciated that the insulators and/or the electrodes may include radiopaque materials or markers so that the endoscope may be viewed fluoroscopically during use. Materials that may be included as conductors are gold, platinum, silver, tungsten, barium sulfide, and bismuth oxide. Examples of radiopaque materials that may be included in the electrodes include, but are not limited to, gold and platinum.


Each electrode 260 is electrically connected to a power source 274, such as an electronic circuit or a simple battery, located at the proximal end of the endoscope or external to the endoscope. In exemplary embodiments, the power source 274 is preferably a low voltage source capable of outputting approximately 3-10 volts. In one embodiment, the power source 274 is a nine (9) volt battery. To electrically connect the electrodes 260 to the power source 274, electrical wires 268, such as copper wires protected in plastic sheaths, may be used. The electrical wires may be disposed along the outer surface 62 or may be routed through the lumen 60 of the endoscope body and through access openings positioned in the endoscope body walls adjacent the electrodes. Alternatively, the electrical wires may be routed through lumens formed in the shaft walls.


As best shown in FIGS. 2A-2B, the electrodes 260 and the power source 274 are configured in a monopolar design. As such, to complete the circuit, a patient return or reference electrode 270 is provided. The patient return or reference electrode 270 is electrically connected to the power source 274. During use, the patient return or reference electrode 270 is connected to the patient, preferably to the exterior of the patient remote from the endoscope. In the embodiment shown, a switch circuit 264 having multiple nodes is connected in between the electrodes 260, 270 and the power source 274 in a conventional manner so that each electrode 260 may be selectively energized one at a time through activation of the switch circuit. It will be appreciated that the switching circuit may be activated by user input or may be programmed to activate according to specific parameters, such as time, images captured by the endoscope, etc.


It will be appreciated that other electrical circuitry, such as multiplexers, may be used to reduce the number of wires 268. Alternatively, the electrodes 260 may be mounted to a flex circuit (not shown) in a conventional manner. The flex circuit may be in the form of sheaths or strips to which power is received from the power source 274 in a conventional manner.


The operation of one exemplary embodiment of the endoscope 20 for selectively releasing or administering a drug agent will now be described with reference to FIGS. 1 and 2A-2B. To use the endoscope 20 in a medical procedure, the distal tip section 48 is inserted into a body opening, such as the anus or the mouth. The endoscope 20 is then advanced through the selected passageways in a conventional manner. As the endoscope 20 is advanced, the distal tip section 48 may be controllably steered using the control wires 204 to navigate the tortuous passageways of the patient.


During the surgical procedure, the endoscope 20 may create discomfort to the patient as the endoscope is steered and advanced around the tortuous passageways. Prior to, during, or after patient discomfort, the physician may administer a localized analgesic at the area of discomfort by activating the drug release control, which signals the release of the drug agent 250 from the outer layer 230. In this particular embodiment, the physician administers the drug agent 250 by selectively sending power to one or more of the electrodes 260. As power travels between the electrodes 260 and 270, the drug agent 250 is forced out of the outer layer 230 and into the patient lumen and surrounding tissue by electrophoresis.



FIG. 4 is a partial longitudinal cross-sectional view of another embodiment of an endoscope 320 formed in accordance with the present invention. The endoscope 320 is substantially similar in materials, construction, and operation as endoscope 20, except for the differences that will now be described. In this embodiment, the electrodes are replaced with heating devices 360, such as silicon-based heating elements, and the outer layer 330 is a thermo-responsive hydrogel that either contracts or expands in response to changes in its temperature. One non-limiting example of a hydrogel that contracts at increased temperatures is poly-isopropylacrylamide. The heating devices 360 may be connected in electrical communication with the power source 374 through the switch circuit (not shown) in such a manner as to selectively produce heat when current is supplied thereto. The switch circuit may be designed such that each heating element 360 may be individually powered to produce heat. It will be appreciated that the switch circuit may also be designed such that combinations of heating elements may be energized simultaneously, if desired.


In use, electrical current is routed to or through one or more of the heating devices 360 and, as a result, causes the heating device 360 to generate heat. The heat generated from the heating device 360 changes (i.e., increases) the ambient temperature of the hydrogel outer layer 330 in the region of the heating device 360 through heat transfer. In response to the increase in temperature, the hydrogel outer layer 330 can either expand or contract, depending on the hydrogel used, thereby releasing the drug agent 350 from the hydrogel outer layer 330.



FIG. 5 illustrates another alternative embodiment of an endoscope 420 that utilizes heat as the signal or stimulus to release the drug agent 450 from its outer layer 430. The endoscope 420 is substantially similar in materials, constructions, and operation as endoscope 20, except for the differences that will now be described. In this embodiment, the electrodes 460, 470 are connected to an RF generator 474 that generates RF energy. The RF generator 474 may selectively deliver RF energy to the electrodes 460, 470 through operation of the switch circuit 464. While the embodiment of FIG. 5 illustrates a return electrode 470 that can be connected to an exterior portion of the patient in a monopolar design, the electrodes may be configured in a bi-polar design, where one reference electrode is disposed proximate to each electrode.


In use, RF energy supplied to the electrodes 460 is transmitted through at least a portion of the outer layer 430 to the return electrode 470 and, as a result, causes the ambient temperature of the outer layer 430, such as a thermo-responsive hydrogel coating, in the region of the electrodes 460 to increase. In response to the change in temperature, the outer layer 430 can either expand or contract, depending on the type of hydrogel used, thereby releasing the drug agent 450 from the hydrogel outer layer 430.



FIG. 6 illustrates another alternative embodiment of an endoscope 520 that utilizes a thermal signal or stimulus to release the drug agent from a thermo-responsive outer layer. The endoscope 520 is substantially similar in materials, construction, and operation as endoscope 20, except for the differences that will now be described. In this embodiment, the drug agent 550 is dispersed within a temperature sensitive hydrogel outer layer 530. The hydrogel outer layer 530 has low viscosity at low temperatures, and becomes solidified when its internal temperature increases. The hydrogel outer layer 530 may be affixed as a coating onto the endoscope 520 via any known techniques. To load the drug agent 550 into the outer layer 530, the endoscope 520 may be lowered into a drug agent solution at a low temperature, such as 30-50 degrees F. Upon warming the outer layer to, for example, 95-100 degrees F., the hydrogel outer layer 530 solidifies, thereby trapping the drug agent 550 therein. To release the drug agent 550 in vivo, the temperature of the outer layer 530 is lowered to “fluidize” the hydrogel outer layer.


In the aforementioned embodiment, a temperature sensitive hydrogel coating may be used as the outer layer 530. This type of temperature sensitive hydrogel coating is known as a lower critical solution temperature (LCST) material. The LCST is the temperature at which the LCST material transitions from a liquid to gel form. Suitable LCST materials that may be practiced with embodiments of the present invention include polyoxyethylene-polyoxypropylene (PEO-PPO) block copolymers. Two examples are pluronic acids 127 and F108 having molecular weights of 12,600 and 14,600, respectively. Each of these examples is commercially available from BASF of Mount Olive, N.J.


In one embodiment, pluronic acid F108 at 20%-28% concentration in phosphate buffered saline (PBS) is used as the hydrogel outer layer 530. In another embodiment, pluronic acid F108 at 22.5 concentration in phosphate buffered saline (PBS) is used as the hydrogel outer layer 530. A preparation of 22% pluronic acid F108 has an LCST of approximately 37 degrees Celsius. In yet another embodiment, pluronic acid F127 at 20%-35% concentration in phosphate buffered saline (PBS) is used at the hydrogel outer layer 530. A preparation of 20% pluronic acid 127 in PBS has an LCST of approximately 37 degrees Celsius. In these embodiments, low concentrations of dye, such as crystal violet, hormones, therapeutic agents, fillers, and antibiotics, can be dispersed in the outer layer 530. For example, a drug agent may be pre-mixed with pluronic acid F127 and the mixture is then loaded onto the shaft of the endoscope. While several examples of LCST outer layers have been described, it will be appreciated that other LCST materials that are biocompatible, biodegradable, and exist as a gel at body temperature and a liquid at below body temperature can be practiced with the present invention. The molecular weight of suitable block copolymers can be, for example, between 5,000 and 25,000.


In this embodiment, fluid delivery conduits 554 that discharge fluids such as water at temperatures lower than the outer layer's LCST in the regions of the drug agent 550 are disposed along the outer surface 562 of the endoscope. The proximal ends of the fluid delivery conduits 554 are fluidly connected to a fluid reservoir 556 via a conventional pump/valve assembly 558. It will be appreciated that the fluid delivery conduits/fluid reservoir may be integrated into the fluid wash system of the endoscope, if desired.


In use, fluid at an appropriate temperature is selectively delivered through fluid delivery conduits 554 to the outer layer 530 and, as a result, causes the ambient temperature of the outer layer 530, such as a LCST coating, in selected regions to decrease. When the temperature of the outer layer 530 decreases below its LCST by the fluid delivered thereto, the outer layer 530 transitions to a more liquid state, thereby releasing the drug agent 550 from the outer layer 530. In several embodiments, the LCST of the outer layer is approximately the internal body temperature of the patient.



FIG. 7 is a longitudinal cross-sectional view of another embodiment of an endoscope 620 formed in accordance with the present invention, which utilizes light energy as the signal or stimulus to selectively release the drug agent 650 from a photosensitive outer layer 630. The endoscope 620 is substantially similar in materials, construction, and operation as endoscope 20, except for the differences that will now be described.


Dimensional changes such as contraction or expansion, including a transition from a liquid to a gel form and vice versa, in response to a light energy signal or stimulus may be induced in photosensitive hydrogels. Such hydrogels may contain a photosensitive compound, e.g., a chromophore, which can absorb light of a specific wavelength and induce a charge transfer that may destabilize a drug/hydrogel interaction and, thus, cause a release of the drug agent from the hydrogel. Absorption of light by the chromophore may also be dissipated as heat, thus increasing the temperature of the hydrogel that, in turn, may induce a dimensional change. For example, poly-propylacrylamide or pluronic acid can be formulated to incorporate a chromophore or chlorophyllin (trisodium salt of copper chlorophyllin). This photosensitive polymer expands (i.e., forms a gel) in the absence of light and collapses or contracts (i.e., transitions to a more liquid state) when exposed to light of a visible wavelength.


Drug agents associated with this type of photosensitive hydrogel composite can be forced out of the hydrogel as contraction of the hydrogel is induced by exposure to a visible wavelength of light. Instead of chlorophyllin, other chromophores or light-sensitive dyes, e.g., rhodamine, may be incorporated into hydrogels to alter the behavior of the hydrogel upon exposure to light.


UV light can also be used to induce a dimensional change in a drug agent-loaded hydrogel to signal drug release. Thus, in another embodiment, the light source may emit UV light into a suitable hydrogel outer layer. Suitable UV light reacting hydrogels, such as those incorporating UV-sensitive compounds, such as leucocyanide or leucohydroxide or derivatives thereof, can be used. For example, a photosensitive copolymer of N-isopropylacrylamide and bis(4-(dimethylamino)phenyl)(4-vinylphenyl) methyl leucocyanide expands when exposed to UV light and contracts when the UV light is removed. Accordingly, the release of drug agents associated with this type of outer layer can be accomplished by selectively emitting UV light from the light source, such as by turning the light generator on and off. Alternatively, drug agent release can be controlled by exposing the hydrogel to two or more different wavelengths of light, one being of a wavelength that signals the release of the drug agent and one of a wavelength that does not signal a release of the drug agent. In this embodiment, the endoscope 620 can be equipped with a light source that can be selectively controlled, i.e., by switching on or off or by altering the wavelength, to signal the release of a drug agent from a photosensitive hydrogel outer layer.


As shown in FIG. 7, a plurality of electromagnetic, radiation-emitting light sources such as fiber optic cables 648 are conventionally connected to a source of electromagnetic radiation 674. The distal ends of the fiber optic cables 648 are disposed along the endoscope outer surface 662. The distal ends of the fiber optic cabling 648 are positioned such that emission of electromagnetic radiation, e.g., visible or ultraviolet light, therefrom contacts, e.g., illuminates, a suitable photosensitive hydrogel outer layer 630 described above. The hydrogel outer layer 630 responds to the electromagnetic radiation by either contracting or expanding. The drug agent 650 is then released from the contracted or expanded outer layer 630.



FIG. 8A is a partial longitudinal cross-sectional view of another embodiment of an endoscope 720 formed in accordance with the present invention that utilizes a chemical signal or stimulus to selectively release the drug agent from a cooperating outer layer 730. The endoscope 720 is substantially similar in materials, construction, and operation as endoscope 20 and 520, except for the differences that will now be described. In this embodiment, the fluid delivery conduits 754 discharge solutions comprising chemical signals in the region of the drug agent 750 along the outer surface 762 of the endoscope. The proximal end of the fluid delivery conduits 754 are fluidly connected to a fluid reservoir 756 via a conventional pump/valve assembly 758.


In one embodiment, the outer layer 730 is an acidic or basic hydrogel coating and the discharge solution includes a pH signal or stimulus that changes the pH in the hydrogel coating, thereby causing expansion and the release of the associated drug agent 750 therefrom.


In other embodiments, the outer layer 730 may be constructed of a protein that degrades in the presence of suitable enzymes. These enzymes may be introduced to the outer layer 730 via user commands or they may be present in specified passageways through which the endoscope travels, such as the gastro tract (pepsin) or the intestinal tract (pancreatin). In the latter embodiments, the drug agent 750 carried by the protein outer layer 730 is released by exposure to the passageway, such as the GI tract. While this embodiment has been described with the outer layer 730 constructed of protein, the outer layer may be omitted and the drug agent 750 may be encapsulated with a substantially identical protein and attached to the endoscope outer surface 762 for subsequent release.


It will be appreciated that other chemical stimuli may be used with cooperatively configured outer layers to selectively release the drug agent therefrom. For example, a change in the ionic strength of a hydrogel outer layer may cause expansion or contraction, thereby releasing the drug agent therefrom.


While the fluid conduits 754 are shown in FIG. 8A as delivering the fluid or chemical stimulus to the inner surface of the outer layer 730, it will be appreciated that the fluid delivery conduits 754 may extend through the outer layer 730 and deliver the fluid or chemical stimulus to the outer surface of the outer layer 730, as best shown in FIG. 8B.


While the preferred embodiments of the invention have been illustrated and described, it will be appreciated that various changes can be made therein without departing from the spirit and scope of the invention. For example, while flexible endoscopes have been illustrated and described, rigid and semi-rigid endoscopes may also be practiced with the present invention. Additionally, one or more types of drug agents may be carried by the outer layer and selectively released therefrom. For example, the proximal region of the endoscope may carry analgesic drug agents to relieve patient discomfort while the distal end may include therapeutic drug agents. It is therefore intended that the scope of the invention be determined from the following claims and equivalents thereof.

Claims
  • 1. A method of selectively releasing an analgesic drug agent from an endoscope in vivo, said method comprising: routing an endoscope through an intestinal tract of a patient's body, wherein said endoscope comprises: (a) a shaft having proximal and distal ends, a working channel lumen, and an outer surface; (b) a hydrogel outermost layer disposed on a portion of the outer surface of the shaft; (c) an analgesic drug agent carried in or on a portion of the hydrogel outermost layer; (d) three or more electrodes spaced apart along a length of the endoscope in contact with the outermost layer, wherein each of the electrodes is adapted to be individually selectively energized; and (e) a stimulus generator associated with the endoscope, the stimulus generator, based upon a selective input, generating an electrical stimulus that causes the drug agent to be released from the hydrogel outermost layer; andselectively energizing said electrodes to release the analgesic drug agent from the hydrogel outermost layer, wherein the analgesic drug agent is delivered locally to a wall of the intestinal tract for relieving patient discomfort.
  • 2. The method of claim 1, wherein selectively releasing of the drug agent includes user input.
  • 3. The method of claim 1, wherein selectively releasing the drug agent includes input based upon environmental conditions.
US Referenced Citations (581)
Number Name Date Kind
3266059 Stelle Aug 1966 A
3470876 Barchilon Oct 1969 A
3572325 Bazell et al. Mar 1971 A
3581738 Moore Jun 1971 A
4108211 Tanaka Aug 1978 A
4286585 Ogawa Sep 1981 A
4294162 Fowler et al. Oct 1981 A
4315309 Coli Feb 1982 A
4351323 Ouchi et al. Sep 1982 A
4425113 Bilstad Jan 1984 A
4432349 Oshiro Feb 1984 A
4471766 Terayama Sep 1984 A
4473841 Murakoshi et al. Sep 1984 A
4488039 Sato et al. Dec 1984 A
4491865 Danna et al. Jan 1985 A
4495134 Ouchi et al. Jan 1985 A
4499895 Takayama Feb 1985 A
4513235 Acklam et al. Apr 1985 A
4515444 Prescott et al. May 1985 A
4516063 Kaye et al. May 1985 A
4519391 Murakoshi May 1985 A
4559928 Takayama Dec 1985 A
4573450 Arakawa Mar 1986 A
4580210 Nordstrom Apr 1986 A
4586923 Gould et al. May 1986 A
4615330 Nagasaki et al. Oct 1986 A
4616630 Arakawa Oct 1986 A
4617915 Arakawa Oct 1986 A
4621618 Omagari et al. Nov 1986 A
4625714 Toyota Dec 1986 A
4631582 Nagasaki et al. Dec 1986 A
4633303 Nagasaki et al. Dec 1986 A
4633304 Nagasaki Dec 1986 A
4643170 Miyazaki et al. Feb 1987 A
4646723 Arakawa Mar 1987 A
4649904 Krauter et al. Mar 1987 A
4651202 Arakawa Mar 1987 A
4652093 Stephen et al. Mar 1987 A
4652916 Suzaki et al. Mar 1987 A
4654701 Yabe Mar 1987 A
RE32421 Hattori May 1987 E
4662725 Nisioka May 1987 A
4663657 Nagasaki et al. May 1987 A
4667655 Ogiu et al. May 1987 A
4674844 Nishioka et al. Jun 1987 A
4686963 Cohen et al. Aug 1987 A
4697210 Toyota et al. Sep 1987 A
4700693 Lia et al. Oct 1987 A
4714075 Krauter et al. Dec 1987 A
4716457 Matsuo Dec 1987 A
4719508 Sasaki et al. Jan 1988 A
4727417 Kanno et al. Feb 1988 A
4727418 Kato et al. Feb 1988 A
4745470 Yabe et al. May 1988 A
4745471 Takamura et al. May 1988 A
4746974 Matsuo May 1988 A
4748970 Nakajima Jun 1988 A
4755029 Okabe Jul 1988 A
4762119 Allred et al. Aug 1988 A
4765312 Sasa et al. Aug 1988 A
4766489 Kato Aug 1988 A
4787369 Allred et al. Nov 1988 A
4790294 Allred et al. Dec 1988 A
4794913 Shimonaka et al. Jan 1989 A
4796607 Allred et al. Jan 1989 A
4800869 Nakajima Jan 1989 A
4805596 Hatori Feb 1989 A
4806011 Bettinger Feb 1989 A
4819065 Eino Apr 1989 A
4819077 Kikuchi et al. Apr 1989 A
4821116 Nagasaki et al. Apr 1989 A
4824225 Nishioka Apr 1989 A
4831437 Nishioka et al. May 1989 A
4836187 Iwakoshi et al. Jun 1989 A
4844052 Iwakoshi et al. Jul 1989 A
4845553 Konomura et al. Jul 1989 A
4845555 Yabe et al. Jul 1989 A
4847694 Nishihara Jul 1989 A
4853772 Kikuchi Aug 1989 A
4860731 Matsuura Aug 1989 A
4867546 Nishioka et al. Sep 1989 A
4868647 Uehara et al. Sep 1989 A
4869237 Eino et al. Sep 1989 A
4873965 Danieli Oct 1989 A
4875468 Krauter et al. Oct 1989 A
4877314 Kanamori Oct 1989 A
4882623 Uchikubo Nov 1989 A
4884134 Tsuji et al. Nov 1989 A
4885634 Yabe Dec 1989 A
4890159 Ogiu Dec 1989 A
4894715 Uchikubo et al. Jan 1990 A
4895431 Tsujiuchi et al. Jan 1990 A
4899731 Takayama et al. Feb 1990 A
4899732 Cohen Feb 1990 A
4899787 Ouchi et al. Feb 1990 A
4905666 Fukuda Mar 1990 A
4918521 Yabe et al. Apr 1990 A
4919112 Siegmund Apr 1990 A
4919114 Miyazaki Apr 1990 A
4920980 Jackowski May 1990 A
4928172 Uehara et al. May 1990 A
4931867 Kikuchi Jun 1990 A
4941454 Wood et al. Jul 1990 A
4941456 Wood et al. Jul 1990 A
4951134 Nakasima et al. Aug 1990 A
4951135 Sasagawa et al. Aug 1990 A
4952040 Igarashi Aug 1990 A
4960127 Noce et al. Oct 1990 A
4961110 Nakamura Oct 1990 A
4967269 Sasagawa et al. Oct 1990 A
4971034 Doi et al. Nov 1990 A
4973311 Iwakoshi et al. Nov 1990 A
4979497 Matsuura et al. Dec 1990 A
4982725 Hibino et al. Jan 1991 A
4984878 Miyano Jan 1991 A
4986642 Yokota et al. Jan 1991 A
4987884 Nishioka et al. Jan 1991 A
4989075 Ito Jan 1991 A
4989581 Tamburrino et al. Feb 1991 A
4996974 Ciarlei Mar 1991 A
4996975 Nakamura Mar 1991 A
5001556 Nakamura et al. Mar 1991 A
5005558 Aomori Apr 1991 A
5005957 Kanamori et al. Apr 1991 A
5007408 Ieoka Apr 1991 A
5018509 Suzuki et al. May 1991 A
5022382 Ohshoji et al. Jun 1991 A
5029016 Hiyama et al. Jul 1991 A
5034888 Uehara et al. Jul 1991 A
5040069 Matsumoto et al. Aug 1991 A
RE33689 Nishioka et al. Sep 1991 E
5045935 Kikuchi Sep 1991 A
5049989 Tsuji Sep 1991 A
5050584 Matsuura Sep 1991 A
5050974 Takasugi et al. Sep 1991 A
5056503 Nagasaki Oct 1991 A
5061994 Takahashi Oct 1991 A
5068719 Tsuji Nov 1991 A
5081524 Tsuruoka et al. Jan 1992 A
5087989 Igarashi Feb 1992 A
5090959 Samson et al. Feb 1992 A
5110645 Matsumoto et al. May 1992 A
5111281 Sekiguchi May 1992 A
5111306 Kanno et al. May 1992 A
5111804 Funakoshi May 1992 A
5113254 Kanno et al. May 1992 A
5119238 Igarashi Jun 1992 A
5131393 Ishiguro et al. Jul 1992 A
5137013 Chiba et al. Aug 1992 A
5140265 Sakiyama et al. Aug 1992 A
5159446 Hibino et al. Oct 1992 A
5170775 Tagami Dec 1992 A
5172225 Takahashi Dec 1992 A
5174293 Hagiwara Dec 1992 A
5176629 Kullas et al. Jan 1993 A
5191878 Iida et al. Mar 1993 A
5198931 Igarashi Mar 1993 A
5201908 Jones Apr 1993 A
5208702 Shiraiwa May 1993 A
5209220 Hiyama et al. May 1993 A
5225958 Nakamura Jul 1993 A
5228356 Chuang Jul 1993 A
5236413 Feiring Aug 1993 A
5243416 Nakazawa Sep 1993 A
5243967 Hibino Sep 1993 A
5257628 Ishiguro et al. Nov 1993 A
5271381 Ailinger et al. Dec 1993 A
RE34504 Uehara et al. Jan 1994 E
5282785 Shapland et al. Feb 1994 A
5291010 Tsuji Mar 1994 A
5299559 Bruce et al. Apr 1994 A
5304121 Sahatjian Apr 1994 A
5311858 Adair May 1994 A
5325845 Adair Jul 1994 A
5331551 Tsuruoka et al. Jul 1994 A
5342299 Snoke et al. Aug 1994 A
5347989 Monroe et al. Sep 1994 A
5374953 Sasaki et al. Dec 1994 A
5379757 Hiyama et al. Jan 1995 A
5381782 DeLaRama et al. Jan 1995 A
5390662 Okada Feb 1995 A
5400769 Tanii et al. Mar 1995 A
5402768 Adair Apr 1995 A
5402769 Tsuji Apr 1995 A
5409485 Suda Apr 1995 A
5412478 Ishihara et al. May 1995 A
5418649 Igarashi May 1995 A
5420644 Watanabe May 1995 A
5431645 Smith et al. Jul 1995 A
5434615 Matumoto Jul 1995 A
5436640 Reeves Jul 1995 A
5436767 Suzuki et al. Jul 1995 A
5440341 Suzuki et al. Aug 1995 A
5464007 Krauter et al. Nov 1995 A
5469840 Tanii et al. Nov 1995 A
5473235 Lance et al. Dec 1995 A
5482029 Sekiguchi et al. Jan 1996 A
5484407 Osypka Jan 1996 A
5485316 Mori et al. Jan 1996 A
5496260 Krauter et al. Mar 1996 A
5507296 Bales et al. Apr 1996 A
5515449 Tsuruoka et al. May 1996 A
5518501 Oneda et al. May 1996 A
5524634 Turkel et al. Jun 1996 A
5543831 Tsuji et al. Aug 1996 A
5569158 Suzuki et al. Oct 1996 A
5569159 Anderson et al. Oct 1996 A
5586262 Komatsu et al. Dec 1996 A
5589854 Tsai Dec 1996 A
5591202 Slater et al. Jan 1997 A
5608451 Konno et al. Mar 1997 A
5619380 Ogasawara et al. Apr 1997 A
5622528 Hamano et al. Apr 1997 A
5631695 Nakamura et al. May 1997 A
5633203 Adair May 1997 A
5643203 Beiser et al. Jul 1997 A
5645075 Palmer et al. Jul 1997 A
5647840 D'Amelio et al. Jul 1997 A
5658238 Suzuki et al. Aug 1997 A
5666965 Bales et al. Sep 1997 A
5667477 Segawa Sep 1997 A
5674182 Suzuki et al. Oct 1997 A
5674197 van Muiden et al. Oct 1997 A
5685823 Ito et al. Nov 1997 A
5685825 Takase et al. Nov 1997 A
5691853 Miyano Nov 1997 A
5695450 Yabe et al. Dec 1997 A
5698866 Doiron et al. Dec 1997 A
5702349 Morizumi Dec 1997 A
5703724 Miyano Dec 1997 A
5704371 Shepard Jan 1998 A
5704896 Fukunishi et al. Jan 1998 A
5704908 Hofmann et al. Jan 1998 A
5707392 Kortenbach Jan 1998 A
5708482 Takahashi et al. Jan 1998 A
5721566 Rosenberg et al. Feb 1998 A
5724068 Sanchez et al. Mar 1998 A
5728045 Komi Mar 1998 A
5739811 Rosenberg et al. Apr 1998 A
5740801 Branson Apr 1998 A
5746696 Kondo May 1998 A
5764809 Nomami et al. Jun 1998 A
5767839 Rosenberg Jun 1998 A
5781172 Engel et al. Jul 1998 A
5788714 Ouchi Aug 1998 A
5789047 Sasaki et al. Aug 1998 A
5793539 Konno et al. Aug 1998 A
5805140 Rosenberg et al. Sep 1998 A
5807306 Shapland et al. Sep 1998 A
5810715 Moriyama Sep 1998 A
5812983 Kumagai Sep 1998 A
5819736 Avny et al. Oct 1998 A
5820591 Thompson et al. Oct 1998 A
5821466 Clark et al. Oct 1998 A
5821920 Rosenberg et al. Oct 1998 A
5823948 Ross, Jr. et al. Oct 1998 A
5827186 Chen et al. Oct 1998 A
5827190 Palcic et al. Oct 1998 A
5828197 Martin et al. Oct 1998 A
5828363 Yaniger et al. Oct 1998 A
5830124 Suzuki et al. Nov 1998 A
5830128 Tanaka Nov 1998 A
5836869 Kudo et al. Nov 1998 A
5837023 Koike et al. Nov 1998 A
5840014 Miyano et al. Nov 1998 A
5841126 Fossum et al. Nov 1998 A
5843000 Nishioka et al. Dec 1998 A
5843016 Lugnani et al. Dec 1998 A
5846183 Chilcoat Dec 1998 A
5855560 Idaomi et al. Jan 1999 A
5857963 Pelchy et al. Jan 1999 A
5865724 Palmer et al. Feb 1999 A
5868664 Speier et al. Feb 1999 A
5868666 Okada et al. Feb 1999 A
5873816 Kagawa et al. Feb 1999 A
5873866 Kondo et al. Feb 1999 A
5876326 Takamura et al. Mar 1999 A
5876331 Wu et al. Mar 1999 A
5876373 Giba et al. Mar 1999 A
5876427 Chen et al. Mar 1999 A
5877819 Branson Mar 1999 A
5879284 Tsujita Mar 1999 A
5880714 Rosenberg et al. Mar 1999 A
5882293 Ouchi Mar 1999 A
5882339 Beiser et al. Mar 1999 A
5889670 Schuler et al. Mar 1999 A
5889672 Schuler et al. Mar 1999 A
5892630 Broome Apr 1999 A
5895350 Hori Apr 1999 A
5897507 Kortenbach et al. Apr 1999 A
5897525 Dey et al. Apr 1999 A
5907487 Rosenberg et al. May 1999 A
5916175 Bauer Jun 1999 A
5923018 Kameda et al. Jul 1999 A
5928136 Barry Jul 1999 A
5929607 Rosenberg et al. Jul 1999 A
5929846 Rosenberg et al. Jul 1999 A
5929900 Yamanaka Jul 1999 A
5929901 Adair et al. Jul 1999 A
5931833 Silverstein Aug 1999 A
5933809 Hunt et al. Aug 1999 A
5935085 Welsh et al. Aug 1999 A
5936778 Miyano et al. Aug 1999 A
5941817 Crawford Aug 1999 A
5950168 Simborg et al. Sep 1999 A
5951462 Yamanaka Sep 1999 A
5951489 Bauer Sep 1999 A
5956416 Tsuruoka et al. Sep 1999 A
5956689 Everhart Sep 1999 A
5956690 Haggerson et al. Sep 1999 A
5959613 Rosenberg et al. Sep 1999 A
5976070 Ono et al. Nov 1999 A
5976074 Moriyama Nov 1999 A
5980454 Broome Nov 1999 A
5980468 Zimmon Nov 1999 A
5986693 Adair et al. Nov 1999 A
5991729 Barry et al. Nov 1999 A
5991730 Lubin et al. Nov 1999 A
5999168 Rosenberg et al. Dec 1999 A
6001088 Roberts et al. Dec 1999 A
6002425 Yamanaka et al. Dec 1999 A
6007531 Snoke et al. Dec 1999 A
6014630 Jeacock et al. Jan 2000 A
6015088 Parker et al. Jan 2000 A
6017322 Snoke et al. Jan 2000 A
6020875 Moore et al. Feb 2000 A
6020876 Rosenberg et al. Feb 2000 A
6022319 Willard et al. Feb 2000 A
6026363 Shepard Feb 2000 A
6030360 Biggs Feb 2000 A
6032120 Rock et al. Feb 2000 A
6039728 Berlien et al. Mar 2000 A
6043839 Adair et al. Mar 2000 A
6050718 Schena et al. Apr 2000 A
6057828 Rosenberg et al. May 2000 A
6059719 Yamamoto et al. May 2000 A
6061004 Rosenberg May 2000 A
6067077 Martin et al. May 2000 A
6071248 Zimmon Jun 2000 A
6075555 Street Jun 2000 A
6078308 Rosenberg et al. Jun 2000 A
6078353 Yamanaka et al. Jun 2000 A
6078876 Rosenberg et al. Jun 2000 A
6080104 Ozawa et al. Jun 2000 A
6081809 Kumagai Jun 2000 A
6083152 Strong Jul 2000 A
6083170 Ben-Haim Jul 2000 A
6095971 Takahashi Aug 2000 A
6099465 Inoue Aug 2000 A
6100874 Schena et al. Aug 2000 A
6104382 Martin et al. Aug 2000 A
6120435 Eino Sep 2000 A
6125337 Rosenberg et al. Sep 2000 A
6128006 Rosenberg et al. Oct 2000 A
6132369 Takahashi Oct 2000 A
6134056 Nakamura Oct 2000 A
6134506 Rosenberg et al. Oct 2000 A
6135946 Konen et al. Oct 2000 A
6139508 Simpson et al. Oct 2000 A
6141037 Upton et al. Oct 2000 A
6142956 Kortenbach et al. Nov 2000 A
6146355 Biggs Nov 2000 A
6149607 Simpson et al. Nov 2000 A
6152877 Masters Nov 2000 A
6154198 Rosenberg Nov 2000 A
6154248 Ozawa et al. Nov 2000 A
6155988 Peters Dec 2000 A
6181481 Yamamoto et al. Jan 2001 B1
6184922 Saito et al. Feb 2001 B1
6193714 McGaffigan et al. Feb 2001 B1
6195592 Schuler et al. Feb 2001 B1
6203493 Ben-Haim Mar 2001 B1
6206824 Ohara et al. Mar 2001 B1
6211904 Adair Apr 2001 B1
6216104 Moshfeghi et al. Apr 2001 B1
6219091 Yamanaka et al. Apr 2001 B1
6221070 Tu et al. Apr 2001 B1
6241668 Herzog Jun 2001 B1
6260994 Matsumoto et al. Jul 2001 B1
6264617 Bales et al. Jul 2001 B1
6272470 Teshima Aug 2001 B1
6275255 Adair et al. Aug 2001 B1
6280411 Lennox Aug 2001 B1
6283960 Ashley Sep 2001 B1
6295082 Dowdy et al. Sep 2001 B1
6299625 Bacher Oct 2001 B1
6309347 Takahashi et al. Oct 2001 B1
6309375 Glines et al. Oct 2001 B1
6310642 Adair et al. Oct 2001 B1
6319196 Minami Nov 2001 B1
6319197 Tsuji et al. Nov 2001 B1
6334844 Akiba Jan 2002 B1
6346075 Arai et al. Feb 2002 B1
6366799 Acker et al. Apr 2002 B1
6381029 Tipirneni Apr 2002 B1
6398724 May et al. Jun 2002 B1
6409716 Sahatjian et al. Jun 2002 B1
6413207 Minami Jul 2002 B1
6421078 Akai et al. Jul 2002 B1
6425535 Akiba Jul 2002 B1
6425858 Minami Jul 2002 B1
6436032 Eto et al. Aug 2002 B1
6441845 Matsumoto Aug 2002 B1
6447444 Avni et al. Sep 2002 B1
6449006 Shipp Sep 2002 B1
6453190 Acker et al. Sep 2002 B1
6454162 Teller Sep 2002 B1
6459447 Okada et al. Oct 2002 B1
6468204 Sendai et al. Oct 2002 B2
6475141 Abe Nov 2002 B2
6478730 Bala et al. Nov 2002 B1
6489987 Higuchi et al. Dec 2002 B1
6496827 Kozam et al. Dec 2002 B2
6498948 Ozawa et al. Dec 2002 B1
6503193 Iwasaki et al. Jan 2003 B1
6520908 Ikeda et al. Feb 2003 B1
6524234 Ouchi Feb 2003 B2
6527759 Tachibana et al. Mar 2003 B1
6530882 Farkas et al. Mar 2003 B1
6533722 Nakashima Mar 2003 B2
6540669 Abe et al. Apr 2003 B2
6544194 Kortenbach et al. Apr 2003 B1
6545703 Takahashi et al. Apr 2003 B1
6551239 Renner et al. Apr 2003 B2
6558317 Takahashi et al. May 2003 B2
6561971 Akiba May 2003 B1
6565507 Kamata et al. May 2003 B2
6569105 Kortenbach et al. May 2003 B1
6574629 Cooke, Jr. et al. Jun 2003 B1
6589162 Nakashima et al. Jul 2003 B2
6595913 Takahashi Jul 2003 B2
6597390 Higuchi Jul 2003 B1
6599239 Hayakawa et al. Jul 2003 B2
6602186 Sugimoto et al. Aug 2003 B1
6605035 Ando et al. Aug 2003 B2
6609135 Omori et al. Aug 2003 B1
6611846 Stoodley Aug 2003 B1
6614969 Eichelberger et al. Sep 2003 B2
6616601 Hayakawa Sep 2003 B2
6623424 Hayakawa et al. Sep 2003 B2
6638214 Akiba Oct 2003 B2
6638215 Kobayashi Oct 2003 B2
6641528 Torii Nov 2003 B2
6651669 Burnside Nov 2003 B1
6656110 Irion et al. Dec 2003 B1
6656112 Miyanaga Dec 2003 B2
6659940 Adler Dec 2003 B2
6663561 Sugimoto et al. Dec 2003 B2
6669629 Matsui Dec 2003 B2
6671561 Moaddeb Dec 2003 B1
6673012 Fujii et al. Jan 2004 B2
6677984 Kobayashi et al. Jan 2004 B2
6678397 Ohmori et al. Jan 2004 B1
6682479 Takahashi et al. Jan 2004 B1
6685631 Minami Feb 2004 B2
6686949 Kobayashi et al. Feb 2004 B2
6690409 Takahashi Feb 2004 B1
6690963 Ben-Haim et al. Feb 2004 B2
6692430 Adler Feb 2004 B2
6692431 Kazakevich Feb 2004 B2
6697101 Takahashi et al. Feb 2004 B1
6699181 Wako Mar 2004 B2
6702737 Hinto et al. Mar 2004 B2
6711426 Benaron et al. Mar 2004 B2
6715068 Abe Mar 2004 B1
6716162 Hakamata Apr 2004 B2
6728599 Wang et al. Apr 2004 B2
6730018 Takase May 2004 B2
6736773 Wendlandt et al. May 2004 B2
6743240 Smith et al. Jun 2004 B2
6749559 Kraas et al. Jun 2004 B1
6749560 Konstorum et al. Jun 2004 B1
6749561 Kazakevich Jun 2004 B2
6753905 Okada et al. Jun 2004 B1
6758806 Kamrava et al. Jul 2004 B2
6758807 Minami Jul 2004 B2
6758842 Irion et al. Jul 2004 B2
6778208 Takeshige et al. Aug 2004 B2
6780151 Grabover et al. Aug 2004 B2
6785410 Vining et al. Aug 2004 B2
6785593 Wang et al. Aug 2004 B2
6796938 Sendai Sep 2004 B2
6796939 Hirata et al. Sep 2004 B1
6798533 Tipirneni Sep 2004 B2
6800056 Tartaglia et al. Oct 2004 B2
6800057 Tsujita et al. Oct 2004 B2
6808491 Kortenbach et al. Oct 2004 B2
6824539 Novak Nov 2004 B2
6824548 Smith et al. Nov 2004 B2
6829003 Takami Dec 2004 B2
6830545 Bendall Dec 2004 B2
6832990 Kortenbach et al. Dec 2004 B2
6840932 Lang Jan 2005 B2
6842196 Swift et al. Jan 2005 B1
6846286 Suzuki et al. Jan 2005 B2
6847933 Hastings Jan 2005 B1
6849043 Kondo Feb 2005 B2
6850794 Shahidi Feb 2005 B2
6855109 Obata et al. Feb 2005 B2
6858004 Ozawa et al. Feb 2005 B1
6858014 Damarati Feb 2005 B2
6860849 Matsushita et al. Mar 2005 B2
6863650 Irion Mar 2005 B1
6863661 Carrillo et al. Mar 2005 B2
6868195 Fujita Mar 2005 B2
6871086 Nevo et al. Mar 2005 B2
6873352 Mochida et al. Mar 2005 B2
6876380 Abe et al. Apr 2005 B2
6879339 Ozawa Apr 2005 B2
6881188 Furuya et al. Apr 2005 B2
6882785 Eichelberger et al. Apr 2005 B2
6887195 Pilvisto May 2005 B1
6890294 Niwa et al. May 2005 B2
6892090 Verard et al. May 2005 B2
6892112 Wang et al. May 2005 B2
6895268 Rahn et al. May 2005 B1
6898086 Takami et al. May 2005 B2
6899673 Ogura et al. May 2005 B2
6899674 Viebach et al. May 2005 B2
6899705 Niemeyer May 2005 B2
6900829 Ozawa et al. May 2005 B1
6902527 Doguchi et al. Jun 2005 B1
6902529 Onishi et al. Jun 2005 B2
6903761 Abe et al. Jun 2005 B1
6903883 Amanai Jun 2005 B2
6905057 Swayze et al. Jun 2005 B2
6905462 Homma Jun 2005 B1
6908427 Fleener et al. Jun 2005 B2
6908429 Heimberger et al. Jun 2005 B2
6911916 Wang et al. Jun 2005 B1
6916286 Kazakevich Jul 2005 B2
6923818 Muramatsu et al. Aug 2005 B2
6928490 Bucholz et al. Aug 2005 B1
6930706 Kobayahi et al. Aug 2005 B2
6932761 Maeda et al. Aug 2005 B2
6934093 Kislev et al. Aug 2005 B2
6934575 Ferre et al. Aug 2005 B2
6943663 Wang et al. Sep 2005 B2
6943946 Fiete Sep 2005 B2
6943959 Homma Sep 2005 B2
6943966 Konno Sep 2005 B2
6944031 Takami Sep 2005 B2
6949068 Taniguchi et al. Sep 2005 B2
6950691 Uchikubo Sep 2005 B2
6955671 Uchikubo Oct 2005 B2
6962564 Hickle Nov 2005 B2
20010039370 Takahashi et al. Nov 2001 A1
20010049491 Shimada Dec 2001 A1
20020017515 Obata et al. Feb 2002 A1
20020028984 Hayakawa et al. Mar 2002 A1
20020055669 Konno May 2002 A1
20020080248 Adair et al. Jun 2002 A1
20020087048 Brock et al. Jul 2002 A1
20020087166 Brock et al. Jul 2002 A1
20020095175 Brock et al. Jul 2002 A1
20020128633 Brock et al. Sep 2002 A1
20020193664 Ross et al. Dec 2002 A1
20030032863 Kazakevich Feb 2003 A1
20030069897 Roy et al. Apr 2003 A1
20030073928 Kortenbach et al. Apr 2003 A1
20030097042 Eino May 2003 A1
20030149338 Francois et al. Aug 2003 A1
20030181905 Long Sep 2003 A1
20030229384 Mon Dec 2003 A1
20040049097 Miyake Mar 2004 A1
20040054258 Maeda et al. Mar 2004 A1
20040073083 Ikeda et al. Apr 2004 A1
20040073084 Maeda et al. Apr 2004 A1
20040073085 Ikeda et al. Apr 2004 A1
20040147809 Kazakevich Jul 2004 A1
20040167379 Akiba Aug 2004 A1
20040183010 Reilly et al. Sep 2004 A1
20040249247 Iddan Dec 2004 A1
20040257608 Tipirneni Dec 2004 A1
20050075538 Banik et al. Apr 2005 A1
20050197536 Banik et al. Sep 2005 A1
20050197861 Omori et al. Sep 2005 A1
20050203341 Welker et al. Sep 2005 A1
20050228697 Funahashi Oct 2005 A1
20060030936 Weber et al. Feb 2006 A1
20060193893 Brown Aug 2006 A1
Foreign Referenced Citations (25)
Number Date Country
0 689 851 Jan 1996 EP
1 300 883 Apr 2003 EP
58-78635 May 1983 JP
05-31071 Feb 1993 JP
05-091972 Apr 1993 JP
06-105800 Apr 1994 JP
06-254048 Sep 1994 JP
07-8441 Jan 1995 JP
10-113330 May 1998 JP
10-286221 Oct 1998 JP
11-216113 Aug 1999 JP
3219521 Aug 2001 JP
2002-102152 Apr 2002 JP
2002-177197 Jun 2002 JP
2002-185873 Jun 2002 JP
2002-253481 Sep 2002 JP
3372273 Nov 2002 JP
2003-075113 Mar 2003 JP
3482238 Oct 2003 JP
WO 9313704 Jul 1993 WO
9604955 Feb 1996 WO
9736632 Oct 1997 WO
9828364 Jul 1998 WO
WO 2004016310 Feb 2004 WO
WO 2005023082 Mar 2005 WO
Non-Patent Literature Citations (2)
Entry
Brannon-Peppas, L., “Polymers in Controlled Drug Delivery,” Medical Plastics and Biomaterials Magazine, Nov. 1997, <http://www.devicelink.com/grabber.php3?URL=http://www.devicelink.com/mpb/archive/97/11/003.html>[retrieved Jul. 17, 2006].
Murdan, S., “Electro-Responsive Drug Delivery From Hydrogels,” Journal of Controlled Release 92:1-17, 2003.
Related Publications (1)
Number Date Country
20070225564 A1 Sep 2007 US